TheraRadar

United

Pre-Approval PRO BETA

Also known as: United Therapeutics, United BioPharma, United Pharmaceuticals

73
Total Trials
29
Phase 3
24
Phase 2
4
Recruiting
697
Score

Pipeline by Phase

Phase 3
29
Phase 2
24
Phase 1
20

Therapeutic Focus

Pulmonary Arterial Hypertension Pulmonary Hypertension HIV-1 Infection Interstitial Lung Disease Hypertension, Pulmonary

Clinical Trials (73)

NCT05943535 Phase 3 RECRUITING

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Started: 10/30/2023

NCT04708782 Phase 3 COMPLETED

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Started: 6/1/2021

NCT04905693 Phase 3 ENROLLING BY INVITATION

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Started: 9/6/2022

NCT03626688 Phase 3 COMPLETED

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Started: 1/24/2019

NCT03794583 Phase 3 TERMINATED

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Started: 12/21/2018

NCT03683186 Phase 3 ENROLLING BY INVITATION

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Started: 9/23/2019

NCT05255991 Phase 3 COMPLETED

Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Started: 10/4/2022

NCT01934582 Phase 3 COMPLETED

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

Started: 8/1/2013

NCT03496623 Phase 3 TERMINATED

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

Started: 5/8/2018

NCT04084678 Phase 3 TERMINATED

A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

Started: 1/20/2021

NCT01560637 Phase 3 COMPLETED

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Started: 9/11/2013

NCT03037580 Phase 3 TERMINATED

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

Started: 8/15/2017

NCT03043651 Phase 3 TERMINATED

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Started: 1/30/2018

NCT01560624 Phase 3 COMPLETED

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

Started: 6/26/2012

NCT02999906 Phase 3 WITHDRAWN

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Started: 10/1/2017

NCT03055234 Phase 3 WITHDRAWN

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Started: 6/1/2017

NCT00760916 Phase 3 WITHDRAWN

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Started: 12/1/2008

NCT00887978 Phase 3 COMPLETED

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension

Started: 6/1/2009

NCT01557647 Phase 3 WITHDRAWN

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH

Started: 6/1/2012

NCT01557660 Phase 3 WITHDRAWN

Inhaled Treprostinil for PAH: Open-label Extension

Started: 6/1/2012

NCT03149211 Phase 3 WITHDRAWN

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

Started: 4/1/2025

NCT04406727 Phase 3 NOT YET RECRUITING

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

Started: 12/1/2023

NCT02711163 Phase 3 COMPLETED

Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula

Started: 4/1/2016

NCT02425423 Phase 3 COMPLETED

Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula

Started: 6/1/2013

NCT02351531 Phase 3 COMPLETED

Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy

Started: 11/1/2013

NCT02276872 Phase 2 COMPLETED

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Started: 12/18/2014

NCT00848107 Phase 2 TERMINATED

Open-Label Study of Oral Treprostinil in Digital Ulcers

Started: 9/1/2009

NCT02261883 Phase 2 TERMINATED

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Started: 7/29/2015

NCT00775463 Phase 2 COMPLETED

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

Started: 5/1/2009

NCT01477333 Phase 2 COMPLETED

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Started: 10/1/2011

NCT01884038 Phase 2 WITHDRAWN

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Started: 6/1/2008

NCT02633293 Phase 2 TERMINATED

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Started: 9/15/2016

NCT02630316 Phase 2 COMPLETED

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Started: 2/3/2017

NCT02279745 Phase 2 COMPLETED

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

Started: 7/8/2015

NCT03098030 Phase 2 COMPLETED

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Started: 6/1/2017

NCT02279160 Phase 2 COMPLETED

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

Started: 12/1/2014

NCT03016468 Phase 2 WITHDRAWN

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Started: 5/1/2017

NCT03012646 Phase 2 WITHDRAWN

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Started: 4/1/2017

NCT01104870 Phase 2 COMPLETED

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

Started: 4/1/2010

NCT01588405 Phase 2 COMPLETED

Remodulin® to Oral Treprostinil Transition

Started: 4/1/2012

NCT02603068 Phase 2 WITHDRAWN

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Started: 2/1/2016

NCT00969722 Phase 2 TERMINATED

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Started: 8/1/2009

NCT05056974 Phase 2 COMPLETED

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

Started: 12/2/2021

NCT03743376 Phase 2 COMPLETED

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

Started: 12/12/2018

NCT04041362 Phase 2 WITHDRAWN

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

Started: 4/1/2020

NCT02369146 Phase 2 COMPLETED

To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

Started: 6/1/2015

NCT06878560 Phase 1 RECRUITING

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

Started: 10/29/2025

NCT07224763 Phase 1 RECRUITING

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

Started: 6/1/2026

NCT03950739 Phase 1 COMPLETED

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

Started: 9/17/2019

NCT03857841 Phase 1 TERMINATED

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

Started: 10/9/2019

NCT01795950 Phase 1 TERMINATED

Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)

Started: 4/1/2013

NCT01592045 Phase 1 COMPLETED

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Started: 8/1/2012

NCT02318758 Phase 1 COMPLETED

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

Started: 9/1/2014

NCT02149095 Phase 1 WITHDRAWN

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

Started: 7/1/2014

NCT01746485 Phase 1 COMPLETED

Three Times Daily Dosing of UT-15C

Started: 7/1/2012

NCT00848939 Phase 1 COMPLETED

Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis

Started: 12/1/2008

NCT01131845 Phase 1 COMPLETED

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

Started: 5/1/2010

NCT01165476 Phase 1 COMPLETED

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

Started: 7/1/2010

NCT01172496 Phase 1 COMPLETED

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

Started: 8/1/2010

NCT01153386 Phase 1 COMPLETED

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

Started: 7/1/2010

NCT00963001 Phase 1 COMPLETED

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Started: 9/1/2009

NCT00963027 Phase 1 COMPLETED

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Started: 9/1/2009

NCT04620304 Phase 1 COMPLETED

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

Started: 1/1/2021

NCT03632291 Phase 1 COMPLETED

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Started: 4/9/2019

NCT02346760 Phase 1 COMPLETED

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers

Started: 12/1/2015

NCT03013881 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

Started: 3/5/2018

NCT05203510 Phase 4 ACTIVE NOT RECRUITING

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Started: 10/20/2022

NCT00643604 Phase 4 TERMINATED

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Started: 3/1/2008

NCT03497689 Phase 4 COMPLETED

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Started: 1/31/2019

NCT02847260 Phase 4 COMPLETED

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

Started: 4/1/2012

NCT02893995 Phase 4 WITHDRAWN

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Started: 2/1/2017

NCT02882126 Phase 4 WITHDRAWN

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Started: 6/1/2017

NCT00741819 Phase 4 COMPLETED

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Started: 9/1/2008

Drug Candidates

Inhaled Treprostinil Ralinepag Inhaled treprostinil solution 10 GE Xenokidney Parenteral Treprostinil Oral Treprostinil GGTA1 KO Thymokidney oral treprostinil Treprostinil Inhalation Powder treprostinil diethanolamine
Activity Status: Active
Last Trial Started: 6/1/2026
Last Trial Ended: 2/2/2026
Trials (12 months): 2
Completed Trials: 40
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.